Find out more about our subscription products and services by visiting our websites: CorporateHealthcareEnergy
Report Store

Search Within Market Intelligence

Keywords:
Search In
Industry:
Pub Month: From  To 
Price Range ($): Min       Max
 
 
 
 
Free Research Alert
Sign up for updates on the latest research
Email: 
 
 
Call us now on +44 1204 543 529
to speak to an advisor
 

PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry

Published: Apr-2013    Report Format:
Report Code: GDHC003PSR
Pharmaceuticals and Healthcare
Single User License
Single User License
$2995
Site License
Site License
$5990
Global License
Global License
$8985
The PharmaSphere: Early-Stage Technology Transfer Collaborations Report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012–2013. GlobalData’s Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industry’s attempts at moving toward an open R&D ecosystem.

Scope

  • Full examination of 25 significant technology transfer deals from 2012 and 2013 involving large pharmaceutical companies and academic organizations including licensing structure and terms
  • Analysis of the key drivers, trends, and strategies behind the deals undertaken by these pharmaceutical companies across major therapeutic areas
  • Discussion of the unsustainability of the current drug research model and how Big Pharma’s embrace of collaboration and an open ecosystem could drive the next wave of scientific discovery
  • Tech Transfer in Action : Each section of the report includes a number of case studies and to highlight major themes within technology transfer
  • Platform assessment on enabling drug technologies being employed by academic research institutions of interest to pharmaceutical companies
  • Breakdown of disruptive innovation trends, including open-source patient data, pre-competitive information sharing, ‘Big Data’ and drug recycling/repurposing approaches


Request Sample Pages

First Name*:
Last Name*:
Company / Organization*:
Email Address*:
Country*:
Phone Number*:  
Time Zone:
Comments:
 
 
 

Report at a Glance

  • Report Code: GDHC003PSR
  • Pages: 85
  • Number of Tables: 27
  • Number of Figures: 6
  • Companies Covered: 23
  • Non-profit / Academia: 32
  • Companies mentioned in this report: Abbott, Accuray, Anchor Therapeutics, AstraZeneca, AyoxxA Biosystems, Bayer, Biscayne, BMS, Boehringer Ingelheim, Élan, Eli Lilly, Genoa Pharma, GSK, J&J, Merck, Novartis, Novo Nordisk, Pfizer, Roche/ Genentech, Sanofi, Synthetic Biologics, Trovagene, and UCB.
  • Non-profit / Academia mentioned in this report: Bill & Melinda Gates Foundation, Brigham & Women’s Hospital, Broad Institute, Calibr, Cambridge University, Cornell Medical College, Duke, Feinstein Institute for Medical Research, Harvard, Juvenile Diabetes Research Foundation, King’s College, McMaster University, National University of Singapore, Oxford, Queensland University, Salk Institute, Scripps Research Institute, Stanford, Texas A&M, Tufts University, UCSD, UCSF, University of British Columbia, University of Dundee, University of Heidelberg, University of Hong Kong, University of Miami, University of Pennsylvania, University of Texas, Vanderbilt University, Washington University in St. Louis, and Yale.
 
 
© GlobalData 2014. John Carpenter House, 7 Carmelite Street, London EC4 O85.